<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1393">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04373460</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00247590</org_study_id>
    <nct_id>NCT04373460</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma to Limit SARS-CoV-2 Associated Complications</brief_title>
  <acronym>CSSC-004</acronym>
  <official_title>Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>State of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bloomberg Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the
      risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or
      oropharyngeal viral shedding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized, double-blind, controlled, phase 2 trial is to evaluate the
      efficacy of treatment with HCIP in reducing hospitalization and death prior to
      hospitalization among outpatient adults who have RNA detection test-confirmed COVID-19 AND
      have developed any symptoms of COVID-19 including but not limited to fever, cough, or other
      COVID associated symptoms like anosmia. Ambulatory/outpatient adults subjects 18 years of age
      or older, regardless of risk factors for severe illness may participate. A total of
      approximately 600 eligible subjects stratified 50:50 in the &lt;65 vs ≥ 65 age range will be
      randomized in a 1:1 ratio to receive either HCIP or control plasma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A total of approximately 600 eligible subjects stratified 50:50 in the &lt;65 vs ≥ 65 age range will be randomized in a 1:1 ratio to receive either HCIP or control plasma.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of hospitalization or death prior to hospitalization</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Cumulative incidence measured as the proportion of subjects who were hospitalized or who died prior to hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of treatment-related serious adverse events</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Cumulative incidence of treatment-related serious adverse events categorized separately as either severe infusion reactions or Acute Respiratory Distress Syndrome (ARDS) during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of treatment-related grade 3 or higher adverse events</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Cumulative incidence measured as the proportion of subjects experiencing a Grade 3 or higher.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum SARS-CoV-2 antibody titers</measure>
    <time_frame>Days 0, 14, 28 and 90</time_frame>
    <description>Analysis of serum SARS-CoV-2 antibody titers will also primarily be descriptive, comparing the geometric mean titers at day 0, 14, 28 and 90 between the randomized arms and calculating the shift or change in the titer distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to SARS-CoV-2 Polymerase Chain Reaction (PCR) negativity</measure>
    <time_frame>Day 0, 14 and 28</time_frame>
    <description>Compare the rates and duration of SARS-CoV-2 RNA positivity (by RT-PCR) of nasopharyngeal or oropharyngeal fluid between active and control groups at days 0, 14 and 28</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in level of SARS-CoV-2 RNA</measure>
    <time_frame>Day 0, 14 and 28</time_frame>
    <description>Compare the levels of SARS-CoV-2 RNA between active and control groups at days 0, 14 and 28</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in oxygen saturation levels</measure>
    <time_frame>Day 0 to Day 28 (where available)</time_frame>
    <description>Comparison of participant self-assessed blood oxygen saturation levels (in percentage oxygen) between treatment arms using pulse oximetry from Day 0 to Day 28.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of participant-reported secondary infection of housemates</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Secondary infection will be assessed by measuring the number of individuals that live in the same house as the active arm who became sick by the end of follow-up period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to ICU admission, invasive mechanical ventilation or death in hospital</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Disease severity measured by time (in days) to admission to the ICU or , invasive mechanical ventilation or time to death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to resolution of COVID-19 symptoms</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Time (in days) to resolution of COVID-19 symptoms will be based on temperature logs and symptom score sheets.</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of convalescent plasma on outcome as assessed by change in hospitalization rate</measure>
    <time_frame>Day 0 to Day 90</time_frame>
    <description>Assess change in hospitalization rate as measured by number of hospitalizations stratified by age groups &lt;65 and &gt;=65</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of donor antibody titers on hospitalizaton rate of convalescent plasma recipients</measure>
    <time_frame>Day 0 to Day 90</time_frame>
    <description>Impact of donor antibody titers (high/low) will be assessed by hospitalization rate as measured by number of hospitalizations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of donor antibody titers on antibody levels of convalescent plasma recipients</measure>
    <time_frame>Day 0 to Day 90</time_frame>
    <description>Impact of donor antibody titers (high/low) will be assessed by antibody levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of donor antibody titers on viral positivity rates of convalescent plasma recipients</measure>
    <time_frame>Day 0 to Day 90</time_frame>
    <description>Impact of donor antibody titers (high/low) will be assessed by viral positivity rates (number of SARS-CoV-2 positive cases per total cases)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1344</enrollment>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>SARS-CoV-2 convalescent plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SARS-CoV-2 convalescent plasma (1 cup; ~200-250 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Control plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 convalescent plasma</intervention_name>
    <description>Plasma collected by apheresis from a volunteer donor who has recovered from COVID-19 and who has SARS-CoV-2 antibody (titer ≥ 1:320 or current FDA standard titer)</description>
    <arm_group_label>SARS-CoV-2 convalescent plasma</arm_group_label>
    <other_name>Human coronavirus immune plasma (HCIP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma from a volunteer donor</intervention_name>
    <description>Plasma collected from a volunteer donor prior to December 31, 2019</description>
    <arm_group_label>Standard Control plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  Competent and capable to provide informed consent

          -  Positive RNA test for presence of SARS-CoV-2 in fluid collected by oropharyngeal or
             nasopharyngeal swab

          -  Experiencing any symptoms of COVID-19 including but not limited to fever(T&gt; 100.5º F),
             cough, or other COVID associated symptoms like anosmia

          -  ≤ 8 days since the first symptoms of COVID-19

          -  ≤ 8 days since first positive SARS-CoV-2 RNA test

          -  Able and willing to comply with protocol requirements listed in the informed consent

        Exclusion Criteria:

          -  Hospitalized or expected to be hospitalized within 24 hours of enrollment

          -  Psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion
             of the principal investigator, would affect subject safety and/or compliance

          -  History of prior reactions to transfusion blood products

          -  Inability to complete therapy with the study product within 24 hours after enrollment

          -  Receiving any treatment drug for COVID-19 within 14 days prior to screening evaluation
             (off label like hydroxychloroquine, compassionate use or study trial related)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David J Sullivan, MD</last_name>
    <phone>410-502-2522</phone>
    <email>dsulliv7@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Sullivan, MD</last_name>
    <phone>410-502-2522</phone>
    <email>dsulliv7@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Hogue, RN, MSN</last_name>
      <phone>205-975-4285</phone>
      <email>ohogue@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Sonya Heath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for American Indian Health - Chinle Office</name>
      <address>
        <city>Chinle</city>
        <state>Arizona</state>
        <zip>86503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Weatherholtz</last_name>
      <phone>410-955-6931</phone>
      <email>rweathe1@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Hammitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Stewart</last_name>
      <email>stewart.lisa@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Janis Blair</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona, Phoenix</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Phillip Esther</last_name>
      <phone>480-284-9219</phone>
      <email>phillipesther@arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Marilyn Glassberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona, Tuscon</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beth Campbell</last_name>
      <email>bsalvag@arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Jarrod Mossier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for American Indian Health - Whiteriver Office</name>
      <address>
        <city>Whiteriver</city>
        <state>Arizona</state>
        <zip>85941</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Weatherholtz</last_name>
      <phone>410-955-6931</phone>
      <email>rweathe1@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Hammitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Corona</last_name>
      <phone>310-794-2512</phone>
      <email>RCorona@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kyron Pierce</last_name>
      <phone>310-794-3908</phone>
    </contact_backup>
    <investigator>
      <last_name>Judith Currier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosie Magallon</last_name>
      <phone>949-824-8297</phone>
      <email>rmagallo@hs.uci.edu</email>
    </contact>
    <investigator>
      <last_name>Don Forthal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Western Connecticut Health Netowrk, Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Camussi</last_name>
      <phone>203-739-7353</phone>
      <email>michael.camussi@wchn.org</email>
    </contact>
    <contact_backup>
      <last_name>Michael Camussi</last_name>
      <phone>914-572-2043</phone>
    </contact_backup>
    <investigator>
      <last_name>Patrick Broderick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Connecticut Health Network, Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin McDonald</last_name>
      <phone>203-739-7353</phone>
      <email>kevin.mcdonald@wchn.org</email>
    </contact>
    <contact_backup>
      <last_name>Kevin McDonald</last_name>
      <phone>732-778-5516</phone>
    </contact_backup>
    <investigator>
      <last_name>Jean Hammel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lissett Moni</last_name>
      <phone>305-355-5315</phone>
      <email>ltueros@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lissett Moni</last_name>
      <phone>305-302-4224</phone>
    </contact_backup>
    <investigator>
      <last_name>Shweta Anjan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittney Adams</last_name>
      <email>BAdams@northshore.org</email>
    </contact>
    <contact_backup>
      <last_name>Margo Quinn</last_name>
      <phone>847-503-4244</phone>
      <email>mquinn@northshore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Giselle Mosnaim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emily Callegari</last_name>
      <phone>504-988-1467</phone>
      <email>ecallegari@tulane.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Callegari</last_name>
      <phone>504-439-0904</phone>
    </contact_backup>
    <investigator>
      <last_name>Hana Safah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Venita Alston-Crawford</last_name>
      <phone>443-481-4393</phone>
      <email>valstoncra@aahs.org</email>
    </contact>
    <investigator>
      <last_name>Barry Meisenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>PlasmaEarlyTreatment@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>David Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Moriarty</last_name>
      <phone>202-877-3657</phone>
      <email>theresa.m.moriarty@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Aarthi Shenoy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Worcester</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Agrillo</last_name>
      <phone>774-455-4456</phone>
      <email>UMassCOVIDplasma@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Gerber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Mazzocco</last_name>
      <phone>313-966-1829</phone>
      <email>tmazzocco@wayne.edu</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Mazzocco</last_name>
      <phone>586-405-9825</phone>
    </contact_backup>
    <investigator>
      <last_name>James Paxton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amber Seik</last_name>
      <phone>505-272-9964</phone>
      <email>aseik@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <phone>505-440-3311</phone>
    </contact_backup>
    <investigator>
      <last_name>Jay Raval</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for American Indian Health - Gallup Office</name>
      <address>
        <city>Gallup</city>
        <state>New Mexico</state>
        <zip>87301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Weatherholtz</last_name>
      <phone>410-955-6931</phone>
      <email>rweathe1@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Hammitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for American Indian Health - Shiprock Office</name>
      <address>
        <city>Shiprock</city>
        <state>New Mexico</state>
        <zip>87420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Weatherholtz</last_name>
      <phone>410-955-6931</phone>
      <email>rweathe1@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Hammitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vassar Brothers Medical Center</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camille Finkle</last_name>
      <phone>845-473-1188</phone>
      <email>cfinkle@health-quest.org</email>
    </contact>
    <contact_backup>
      <last_name>Camille Finkle</last_name>
      <phone>845-242-2568</phone>
    </contact_backup>
    <investigator>
      <last_name>Valerie Cluzet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Heininger</last_name>
      <phone>585-273-1926</phone>
      <email>Susanne_Heininger@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Zand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Kohrs</last_name>
      <phone>513-584-6383</phone>
      <email>kohrssd@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Moise Huaman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lifespan/BrownUniversity (Rhode Island Hospital)</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Suarez</last_name>
      <email>ESuarez@Lifespan.org</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Basso</last_name>
      <phone>401-444-2936</phone>
      <email>kristin.basso@lifespan.org</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Levine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zohra Huda</last_name>
      <phone>713-798-6060</phone>
      <email>COVID-19/CP@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Yuriko Fukuta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Ayad</last_name>
      <phone>713-704-5198</phone>
      <email>mary.ayad@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Bela Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priscilla Rosen</last_name>
      <phone>801-213-3401</phone>
      <email>priscilla.rosen@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Emily Spivak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual participant data (IPD) collected in this study, including data dictionaries, will be made available to other researchers after the end of the study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After publication of initial study manuscript</ipd_time_frame>
    <ipd_access_criteria>Public</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

